Amedisys (AMED) Tops Q2 EPS by 10c

Amedisys (NASDAQ: AMED) reported Q2 EPS of $0.43, $0.10 better than the analyst estimate of $0.33. Revenue for the quarter came in at $314.2 million versus the consensus estimate of $307.11 million.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• UBS Downgrades Mondi PLC (MNDI:LN) (MONDY) to Neutral
• UBS Downgrades EasyJet Plc. (EZJ:LN) (ESYJY) to Neutral